UC (urothelial)
Oncology · 2018–2023
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| nivolumab Adjuvant treatment of high-risk muscle invasive urothelial carcinoma (MIUC) after radical surgical resection in patients who have received prior neoadjuvant… | Nov 2023 | Deferred | input received Medical Oncology Group |
| nivolumab Adjuvant treatment of patients who have undergone radical resection of muscle invasive urothelial carcinoma (MIUC) originating in the bladder or upper urinary… | Jul 2022 | Not recommended | input received BEAT Bladder Cancer Australia · Medical Oncology Group |
| pembrolizumab Locally advanced (Stage III) or metastatic (Stage IV) urothelial cancer in patients after failure of platinum-containing chemotherapy. | Jul 2018 | Recommended with restriction | 10 individuals Medical Oncology Group |
Who spoke
Medical Oncology Group · BEAT Bladder Cancer Australia
What the PBS pays
$825M in government benefit over 2024–25, across 95,092 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| pembrolizumab | $739.6M |
| nivolumab | $85.2M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.